US20060105372A1 - Compositions and methods for purifying nucleic acids from stabilization reagents - Google Patents
Compositions and methods for purifying nucleic acids from stabilization reagents Download PDFInfo
- Publication number
- US20060105372A1 US20060105372A1 US11/265,996 US26599605A US2006105372A1 US 20060105372 A1 US20060105372 A1 US 20060105372A1 US 26599605 A US26599605 A US 26599605A US 2006105372 A1 US2006105372 A1 US 2006105372A1
- Authority
- US
- United States
- Prior art keywords
- sample
- solution
- rna
- concentration
- solid support
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Definitions
- This invention relates to materials and methods for isolating RNA, DNA, or both, from a sample.
- Nucleic acids such as deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are used extensively in the field of molecular biology for research and clinical analyses.
- RNA is highly sensitive to degradation. Therefore, methods also exist for protecting RNA from enzymatic digestion by RNA degrading enzymes (e.g., RNases). The RNA can then be separated from the DNA, protein, and other contaminants. These isolation processes are usually performed in a stepwise fashion, wherein cells are lysed under conditions that inhibit RNase activity, followed by further purification, in separate steps. Methods have also been developed to stabilize RNA at the point of collection to permit storage of the sample prior to further purification of the RNA.
- RNA degrading enzymes e.g., RNases
- Formulations and methods featured by the present invention allow for the extraction and purification of RNA, or DNA, or both, from the same sample, thus providing an advantage to users. Additionally, formulations and methods featured by the present invention can be used with collection tubes from many manufacturers, thus providing a simple, flexible, and cost-effective solution for the user, regardless of the collection tube they choose.
- the present invention provides a method for isolating RNA from a test sample containing RNA involving preparation of a crude lysate from a stabilized sample, contacting the crude lysate with a Solubilization Solution comprising a buffer at a pH between about 7 and 9, a base, an amphiphillic reagent; contacting the sample with a Lysis Solution buffered at a pH of greater than about 7 to create an isolation sample, wherein the Lysis Solution comprises a complexing salt; contacting the isolation sample to a solid support such that nucleic acids comprising substantially undegraded RNA in the isolation sample bind to the solid support; washing the solid support with one or more Wash Solutions to remove materials other than bound nucleic acids comprising substantially undegraded RNA; and eluting the bound substantially undegraded RNA from the solid support in order to obtain substantially pure and undegraded RNA.
- a Solubilization Solution comprising a buffer at a pH between about 7 and 9, a base, an amphiphillic
- the present invention also provides a method for isolating DNA from a test sample containing DNA involving preparation of a crude lysate from a stabilized sample, contacting the crude lysate with a Solubilization Solution comprising a buffer comprising a buffer at a pH between about 7 and 9, a base, an amphiphillic reagent; contacting the sample with a Lysis Solution buffered at a pH of greater than about 7 to create an isolation sample, wherein the Lysis Solution comprises a complexing salt; contacting the isolation sample with either (i) a Binding Solution comprising a buffer, a lithium salt, and an amphiphillic reagent, or (ii) a wash solution comprising a lithium salt and an alcohol to create a binding sample; contacting the binding sample to a solid support such that nucleic acids comprising substantially undegraded DNA in the binding sample bind to the solid support; washing the solid support with one or more Wash Solutions to remove materials other than bound nucleic acids comprising substantially undegraded DNA
- the present invention further provides a method for isolating both DNA and RNA from a sample involving dividing the sample into a first and second tube (or dividing the sample after the Solubilization Solution is added to the sample); isolating the RNA from the sample in the first tube according to the RNA isolation method described above; and isolating the DNA from the sample in the second tube according to the DNA isolation method described above.
- the present invention also provides a method for isolating substantially pure and undegraded RNA from a test sample containing RNA.
- the method involves contacting the test sample stabilized with a guanidinium stabilizing agent, such as the TempusTM stabilizing agent (see, e.g., U.S. Pat. No.
- Alcohols that can be used in this process can be either ethanol or methanol or a combination of methanol and ethanol.
- the alcohol is present in a concentration of between about 30% and 100%, or between 70% and 95%.
- the guanidinium from the stabilizing agent is substantially removed, so that the crude lysate pellet is substantially free of guanidinium.
- substantially free of means that less than 1% (e.g., less than 0.5% or 0.1%, or even less than 0.01%) of the original starting volume of the stabilizing agent is present in the crude lysate. Any residual guanidinium that may remain will not have an impact on the chemistry of subsequent purification processes.
- the present invention provides a formulation for solubilizing a material containing nucleic acids, where the formulation contains Tris-HCl at a concentration of about 10 to 20 mM and at a pH between about 7 and 9, Tris base at a concentration of about 20 to 50 mM, Triton-X at a concentration of about 5 to 15%, and EDTA at a concentration of about 1 to 20 mM.
- the present invention provides a kit for isolating RNA, DNA, or both, which comprises packaging, containing (separately packaged) a Solubilization Solution, a Lysis Solution, a Wash I Solution or Binding Solution, a Wash II Solution, and a protocol for isolation of RNA, DNA, or both, from a sample.
- FIG. 1 is a flow diagram depicting the procedure one would use to isolate DNA, RNA, or both, from a sample collected in PAXgene Blood RNA collection tubes or to isolate RNA from a sample collected in Tempus Blood RNA collection tubes using the present invention.
- FIGS. 2-4 illustrate the effect of using different diluents and centrifugation conditions for the preparation of a crude lysate from a Tempus Blood RNA collection tube.
- ribonucleic acids provide extensive information of the genetic origin and the functional activity of cells. Such information can be used, for example, in clinical practice, to diagnose infections, detect the presence of cells expressing oncogenes, detect heredity disorders, monitor the state of host defense mechanisms, investigate and diagnose metabolic diseases, investigate influence of drugs on gene expression in patients, and investigate side and toxic effects of drugs.
- nucleic acid purification methods exist that fall into two general categories, liquid phase purification and solid phase purification.
- liquid phase purification nucleic acids remain in the liquid phase, while impurities are removed by precipitation and/or centrifugation. Alternatively, nucleic acids are precipitated out while the impurities remain.
- solid phase purification the nucleic acids are bound to a solid support, while impurities are selectively eluted.
- RNA isolated by liquid phase purification remains in the liquid phase, while impurities are removed by processes such as precipitation and/or centrifugation.
- solid phase purification RNA is bound to a solid support while impurities such as DNA, proteins, and phospholipids are selectively eluted.
- Both purification categories aim at yielding substantially undegraded RNA. Both purification strategies utilize conventional methods, which require numerous steps and, often, hazardous reagents, as well as more rapid methods, which require fewer steps and usually less hazardous reagents.
- the starting material e.g., biological material
- both the liquid and solid methods require a cell or viral co-rupture, or a lysis step. A rupture, or lysis, step results in RNA mixed with contaminants such as DNA, lipids, carbohydrates, proteins, etc. Such a mixture also contains RNases that degrade RNA and must be removed and/or inactivated, so as to not interfere with yielding substantially undegraded RNA.
- liquid phase RNA isolation methods have used liquid-liquid extraction (i.e., phenol-chloroform) and alcohol precipitation.
- liquid-liquid RNA extraction method is the “acid-guanidinium-phenol” method of Chomczynski and Sacchi (Chomczynski P., Sacchi N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, Anal Biochem 162: 156-9 [1987]; U.S. Pat. Nos. 5,945,515, 5,346,994, and 4,843,155).
- This method includes: (1) extracting a sample with a guanidinium isothiocyanate (GITC) solution to which an acidic medium, phenol, and chloroform are added consecutively; (2) centrifuging the mixture to separate the phases, such that the proteins denatured by the phenol may be removed from the nucleic acids that are found in an intermediate layer; (3) adding an alcohol so as to precipitate, and thereby concentrate the RNA; and (4) washing and re-hydrating the purified RNA.
- GITC guanidinium isothiocyanate
- Precipitation of nucleic acids by cationic detergents is another example of liquid phase technology (U.S. Pat. Nos. 5,985,572; 5,728,822 and 5,010,183 (MacFarlane)).
- U.S. Pat. No. 5,985,572 discloses a method for isolating RNA from biological samples using selected quaternary amine surfactants.
- a non-hazardous liquid phase purification method was disclosed by Heath (U.S. Pat. No. 5,973,137) using low pH lysing and precipitation reagents.
- Heath U.S. Pat. No. 5,973,137
- liquid phase methods have serious disadvantages in that they involve tedious precipitation steps, and are consequently difficult to automate.
- RNA isolation involves homogenizing cells in guanidinium isothiocyanate, followed by a sequential addition of sodium acetates and phenol, and chloroform/isoamyl alcohol.
- Some methods for lysing cells and inhibiting RNases are known that use chaotropic salts of guanidinium. After centrifugation, RNA is precipitated from the upper layer by the addition of alcohol. Other methods include the addition of hot phenol to a cell suspension, followed by alcohol precipitation. These methods are hazardous to the user, and disposal of the reagents that are used can be costly.
- Substantially undegraded DNA can be isolated by a variety of liquid and solid phase methods known to those having ordinary skill in the art.
- DNA can be isolated by routine techniques such as described in Maniatis et al., 1989 (in Molecular Cloning, A Laboratory Manual, Cold Springs Harbor Laboratory, NY), or in Persing et al. (eds.) (1993), Diagnostic Molecular Microbiology: Principles and Applications (American Society for Microbiology, Washington D.C.).
- 5,234,809 (Boom et al.) uses a high concentration chaotropic solution to bind DNA to silica particles and requires six centrifugation steps and five reagents to purify DNA from whole blood. Disadvantages of this method are the use of a particulate suspension, the use of many centrifugation steps, and the use of hazardous reagents, such as guanidinium isothiocyanate and acetone.
- U.S. Pat. No. 5,496,562 (Burgoyne) describes a method of purifying cellulose filter paper containing dried blood that uses four reagents during four phenol washes and five isopropanol washes. After drying, a small piece of the filter paper is cut from the square and used directly as a substrate for PCR amplification. Despite the use of bound DNA for analysis, these methods still require many steps and hazardous reagents.
- Samples can be collected by a variety of means.
- sample collection containers are used for collecting and storing samples.
- collection containers are glass or plastic tubes having a resilient stopper.
- blood collection tubes are used, where the tube is evacuated to draw a volume of blood into the tube.
- collection tubes can have various additives, such as ethylenediaminetetraacetic acid (EDTA) contained therein, in order to prepare the blood sample for a particular test.
- the additive is an anticoagulation agent.
- the anticoagulation additive is a buffered citrate or heparin in an aqueous solution.
- the aqueous citrate is combined with the blood sample in a specified amount to determine the amount of an anticoagulant needed for conducting certain tests.
- Such treated collection tubes are used mainly for serological testing, since the additives do not stabilize nucleic acids in the sample.
- Sample-collection containers are used for collecting and/or storing a variety of samples.
- sample collection containers are used to collect and/or store biological fluids or samples (e.g., whole blood, bone marrow, blood spots, blood serum, blood plasma, buffy coat preparations, saliva and cerebrospinal fluid, buccal swabs, cultured cells, cell suspensions of bacteria, solid animal tissues such as heart, liver and brain, body waste products, such as feces and urine, environmental samples taken from air, water, sediment or soil, plant tissues, yeasts, bacteria, viruses, mycoplasmas, fungi, protozoa, rickettsia, and other small microbial cells).
- sample collection containers are used to collect and/or store lysates, homogenates, or partially purified samples of biological materials.
- biological materials include crude or partially purified mixtures of nucleic acids.
- Applied Biosystems markets and sells blood collection tubes for the stabilization of RNA.
- the trade name of these tubes is TempusTM RNA collection tubes. These tubes use a formulation containing guanidine hydrochloride. This product's solution stabilizes total RNA from whole blood for up to five days at room temperature.
- RNAlater® solution This reagent uses a formulation of ammonium sulfate.
- RNAlater® is an aqueous tissue and cell storage reagent that stabilizes and protects cellular RNA in intact, unfrozen tissue, and cell samples. RNAlater® eliminates the need to immediately process samples or to freeze samples in liquid nitrogen for later processing. A user cuts tissue samples to be stored, so they are less than 0.5 cm in at least one dimension, and submerges them in five volumes of RNAlater® until they are ready to purify the nucleic acids from the sample.
- RNAsafer® Stabilizer Reagent Omega Bio-Tek markets and sells a reagent for stabilization of RNA.
- the trade name of this reagent is RNAsafer® Stabilizer Reagent. Once this reagent is applied to a sample, it penetrates cells and tissues, and inactivates RNases at room temperature. Samples can be stored in RNAsafer® Stabilizer Reagent for up to 12 months at ⁇ 20° C.
- the present invention features several categories of reagents: Diluent Solution, Solubilization Solution, Lysis Solution, Proteinase K Solution, Binding Solution, Wash Solutions, and Elution Solutions.
- Diluent Solution In some embodiments a diluent is added to a biological material in the presence of a stabilizing agent to facilitate the preparation of a crude lysate.
- a stabilizing agent to facilitate the preparation of a crude lysate.
- the manufacturer of TempusTM solutions (Applied Biosystems, Inc.) specifies that PBS be used.
- the PAX system does not require a Diluent solution.
- alcohol was used to improve robustness of the process.
- Solubilization Solution A Solubilization Solution is used to solubilize a sample pellet following centrifugation to generate a crude lysate.
- the Solubilization Solution formulation includes a buffer, a base, an amphiphillic reagent, such as a detergent or surfactant or mixture thereof, and an optional chelator.
- the Solubilization Solution may contain a buffer, such as Tris HCl, at a pH between 7-9 (e.g., pH 7.1, 7.3, 7.5, 7.8, 8.0, 8.2, 8.6, 8.8, 8.9, or 9).
- the buffer concentration may be at 10-20 mM (e.g., at 10.5 mM, 11 mM, 11.7 mM, 12 mM, 12.5, mM, 13 mM, 13.6 mM, 14 mM, 14.2 mM, 14.8 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, or 19.5 mM).
- a base concentration may be at 20-50 mM (e.g., Tris base at 21 mM, 25 mM, 27 mM, 31 mM, 35 mM, 38 mM, 42 mM, 47 mM, or at 49 mM).
- the Solubilization Solution may additionally include an amphiphillic reagent.
- An amphiphillic reagent includes a compound or a molecule having a hydrophilic group attached to a hydrophobic functionality, such as a hydrocarbon chain, and having surfactant properties.
- the amphiphillic reagent is a detergent.
- Anionic, cationic, and zwitterionic detergents may be used.
- a non-ionic detergent is used in nucleic acid isolation.
- non-ionic detergents from the Tween class are used (e.g., Tween-20, Tween-40, Tween-60, Tween-80, etc.).
- Triton class detergents are used (e.g., X-100, X-114, XL-80N, etc).
- Tergitols e.g., XD, TMN-6
- Nonidets or Igepal e.g., NP-40
- the nonionic detergent is used at a concentration of 5-15% (e.g., Triton-X at about 5%, 7%, 8%, 10%, 12%, or 14%).
- the chelating agent ethylenediaminetetraacetic acid (EDTA) is added at a concentration of 1-20 mM (e.g., at 5-10 mM, 6-9 mM, 7-8 mM, 8 mM, or 7.5 mM)
- a Lysis Solution enables efficient lysis (e.g., of cells in a biological sample) to release nucleic acids, effectively inhibits nucleic acids-degrading enzymes' activity, and allows nucleic acids to bind to a solid support of choice.
- a Lysis Solution of the present invention contains a buffer (such as Tris-HCl), an alkali-metal salt (such as Sodium salts, for example sodium chloride, or Lithium salts, for example lithium chloride or lithium bromide), an amphiphillic reagent (such as a detergent, or surfactant, or a mixture thereof), and optionally chelating reagents (such as EDTA or CDTA).
- a buffer such as Tris-HCl
- an alkali-metal salt such as Sodium salts, for example sodium chloride, or Lithium salts, for example lithium chloride or lithium bromide
- an amphiphillic reagent such as a detergent, or surfactant, or a mixture thereof
- a Lysis Solution of the present invention is unique in that it requires no added strong chaotropic substances such as guanidinium salts, urea, etc.
- Guanidinium salts and urea are strong chaotropic salts that disrupt the structure of water and thus tend to decrease the strength of hydrophobic interactions resulting in a drastic effect on other solute molecules.
- urea when dissolved in water, disrupts the secondary, tertiary, and quaternary structures of proteins, and subsequently causes dissociation of proteins from RNA. Guanidinium salts and urea dissolve in water through endothermic reactions.
- guanidinium salts and urea are considered to be strong chaotropic salts as defined by the Hofmeister series, a widely used system that ranks cations and anions according to relative chaotropic strength (F. Hofmeister, On the understanding of the effects of salts, Arch. Exp. Pathol. Pharmakol . (Leipzig) 24 (1888) 247-260).
- alkali-metal salts e.g., sodium chloride, lithium chloride and lithium bromide
- the reaction of alkali-metal salts, in water is an exothermic reaction and is indicative of the tremendous ion-dipole interaction exhibited by the strong kosmotropic lithium ion and the resulting large solubility. Differences such as these are indicative of the differences between the strong chaotropic substances, such as guanidinium salts, and the alkali-metal salts, especially lithium chloride, of the present invention.
- a first component of the Lysis Solution is a buffer that maintains the pH of the solution (e.g., a Tris buffer or any known buffer).
- the pH of the buffer may be at least about 8, at least about 8.5, or even at least about 9 (e.g., 8.1, 8.4, 8.6, 8.7, 8.9, 9.1, or 9.5).
- the buffer may have a pKa of at least about 8 (e.g., 8.1, 8.3, 8.5, 8.6, 8.8, or 8.9), and may be used at a concentration of 50-150 mM (e.g., 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 120 mM, or 140 mM).
- Tris buffer is an appropriate buffer. In some instances, Tris buffer with a pH of 8.0 and a concentration of 100 mM is used. In some other embodiments, a base may be used to adjust the pH of the Lysis Solution. The base may be one that can raise the pH of the solutions to no less than 7 (e.g., pH 7.5, 8, 8.5, or 9.0). In some instances, the base may be an alkali-metal hydroxide. Such alkali-metal hydroxides include, but not limited to, sodium hydroxide, potassium hydroxide, and lithium hydroxide.
- a Lysis Solution Another component of a Lysis Solution is a complexing salt that confers unique binding properties to nucleic acids (e.g., an RNA-complexing salt), such that the nucleic acids can preferentially bind to a solid support instead of other contaminants such as proteins, phospholipids, etc.
- a complexing salt may be any known complexing salt, such as sodium salt, or lithium salt, such as lithium chloride or lithium bromide.
- the salt may be present at a concentration of between 3-10 M (e.g., 4 M, 5 M, 6 M, 7 M, 8 M, or 9 M), because preferential binding of DNA and RNA to a solid support is enhanced by high concentrations of alkali-metal salts.
- lithium chloride is used in the Lysis Solution, at a concentration of 4 M.
- a Lysis Solution additionally includes one or more amphiphillic reagents.
- An amphiphillic reagent includes a compound or molecule having a hydrophilic group attached to a hydrophobic functionality, such as a hydrocarbon chain, and having surfactant properties.
- the amphiphillic reagent is a detergent. Although anionic, cationic, and zwitterionic detergents may all be used, nucleic acid isolation is optimally achieved through the use of a non-ionic detergent.
- non-ionic detergents examples are those from the Tween class (Tween-20, Tween-40, Tween-60, Tween-80, etc.), the Triton class (X-100, X-114, XL-80N, etc), Tergitols (XD, TMN-6, etc.) and Nonidets or Igepal (NP-40, etc.).
- the nonionic detergent may be used at a concentration of 5-15% (e.g., at about 10%, 11%, 12%, 13%, or 14%).
- the amphiphillic reagent is a surfactant, such as diethylene glycol monoethyl ether (DGME).
- DGME diethylene glycol monoethyl ether
- the surfactant may be used at a concentration of 5-15% (e.g., 6%, 10%, 11%, 12%, 13%, or 14%).
- a combination of detergents and surfactants may be used.
- a combination of detergent and surfactant Triton-X and DGME is used.
- the combination may be at a concentration of 5-15% (e.g., 10%, 11%, 12%, 13%, or 14%).
- the combination is 5% Triton-X and 5% DGME.
- nuclease-free water is used in the Lysis Solution.
- a chelating agent also may be used to prevent degradation of contaminating nucleic acid. The use of a chelating agent prevents nucleic acid polymers from being degraded to smaller fragments, which may cause additional contamination problems.
- the chelating agent may be present at a concentration of 1-100 mM (e.g., 2 mM, 5 mM, 8 mM, 10 mM, 15 mM, 20 mM, 25 mM, 35 mM, 45 mM, 50 mM, 65 mM, 75 mM, 85 mM, or 95 mM), or at a concentration of 1-10 mM (e.g., 1.5 mM, 2 mM, 3 mM, 4 mM, 6 mM, 7 mM, or 9 mM).
- the chelating agent EDTA is used.
- the chelating agent CDTA is used.
- the Lysis Solution of the present invention is advantageous.
- the unique combination of a high concentration of a complexing salt and a high concentration of a detergent in a neutral- to high-pH buffer inactivates enzymes harmful to nucleic acids (such as RNases), without the use of such reagents as phenol, chloroform, and guanidinium salts.
- the solution confers a high binding property to the nucleic acids such that they tightly bind with the solid support of choice.
- Optional Proteinase K Solution In some embodiments, during RNA purification, a user performs an additional Proteinase K step. In some embodiments, during DNA purification, a user performs an additional Proteinase K step.
- a suitable Proteinase K Solution includes about 10 to 25 mg/mL Proteinase K (e.g., 10 mg/mL, 15 mg/mL, or 25 mg/mL). In certain instances, a suitable Proteinase K Solution has a concentration of 20 mg/mL Proteinase K.
- the Binding Solution may be used when purifying DNA from a Stabilized Sample in order to improve the binding of DNA to the solid support.
- the binding may be improved through significant increase in salt concentration, or by dehydration, or both.
- the present invention features a Binding Solution that has the following components: a buffer, an alkali metal salt, and an amphiphillic reagent, such as a detergent or surfactant or mixture thereof.
- the first component of the Binding Solution is a buffer that maintains the pH of the solution.
- the pH may be at least about 7 (e.g., 7.5, 8, 8.5, 9, or 9.5).
- the buffer may be used at a concentration of 50-150 mM (e.g., 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 120 mM, or 140 mM).
- Tris buffer is an appropriate buffer.
- a base may be used to adjust the pH of the Binding Solution.
- the base may be one that can raise the pH of the solutions to no less than 7 (e.g., pH 7.5, pH 8, pH 8.5, or pH 9.0).
- the base may be an alkali-metal hydroxide.
- alkali-metal hydroxides include sodium hydroxide, potassium hydroxide, and lithium hydroxide.
- a complexing salt that confers unique binding properties to nucleic acids, such that the nucleic acids can preferentially bind to the solid support over other contaminants such as proteins, phospholipids, etc.
- a complexing salt may be any known complexing salt, such as a sodium salt or lithium salt, such as lithium chloride or lithium bromide.
- the salt may be present at a concentration of between 5-15 M (e.g., at about 6 M, 7 M, 8 M, 9 M, 10 M, 11 M, 12 M, 13 M, or at about 14 M) because preferential binding of DNA to a solid support is enhanced by high concentrations of alkali-metal salts.
- amphiphillic reagent Another component of the Binding Solution is an amphiphillic reagent.
- An amphiphillic reagent includes a compound or molecule having a hydrophilic group attached to a hydrophobic functionality, such as a hydrocarbon chain, and having surfactant properties.
- the amphiphillic reagent is a detergent. Although anionic, cationic, and zwitterionic detergents may all be used, nucleic acid isolation is optimally achieved through the use of a non-ionic detergent.
- non-ionic detergents examples are those from the Tween class (Tween-20, Tween-40, Tween-60, Tween-80, etc.), the Triton class (X-100, X-114, XL-80N, etc), Tergitols (XD, TMN-6, etc.) and Nonidets or Igepal (NP-40, etc.).
- the nonionic detergent may be used at a concentration of 5-15% (e.g., at about 10%, 11%, 12%, 13%, or 14%).
- the amphiphillic reagent is a surfactant, such as diethylene glycol monoethyl ether (DGME).
- DGME diethylene glycol monoethyl ether
- the surfactant may be used at a concentration of 5-15% (e.g., 6%, 10%, 11%, 12%, 13%, or 14%).
- a combination of detergents and surfactants may be used.
- a combination of detergent and surfactant Triton-X and DGME is used.
- the combination may be at a concentration of 5-15% (e.g., 10%, 11%, 12%, 13%, or 14%).
- the combination is 5% Triton-X and 5% DGME.
- the detergent or surfactant may be anionic, cationic, zwitterionic or nonionic.
- a nonionic detergent is used. It has been observed that some charged detergents such as SDS, do not remain solubilized in higher concentration salt solutions and in fact, they may tend to precipitate rather quickly. It is possible however, to use such charged detergents under certain experimental conditions, including but not limited to those described in one embodiment of the present invention, for pre-treating the solid support.
- non-ionic detergents include detergents from the Tween, Triton, Tergitol and Nonidet or Igepal classes of detergents.
- the surfactant is DGME (diethyl glycol monoethyl ether).
- Wash I may be used as a Binding Solution.
- wash Solutions The present invention also teaches of one or more wash solutions that are used to wash the solid support to which nucleic acids are bound, so as to rid it of non-nucleic acid contaminants such as proteins, phospholipids, etc.
- the wash solutions may contain an alcohol at a concentration greater than 50% (e.g., 60%, 70%, 80%, 90%, 95%, or 100%).
- the alcohol can be, for example, ethanol or methanol. In some embodiments, ethanol is used at a concentration of 75%. In other embodiments, methanol is used at a concentration of 65%.
- the Wash I Solution contains a high alkali metal salt concentration, such as a sodium or lithium salt (e.g., lithium chloride or lithium bromide), at a concentration between 4-10 M (e.g., 5-6 M, 4-7M, 5-8M, 6-9M, 6-10M, 7-10M, 5 M, 6 M, 7 M, 8 M, 9 M, or 10 M).
- a high salt concentration means a salt concentration high enough to inhibit enzyme activity, to complex to nucleic acid, and to provide a salting-out effect for binding of nucleic acid to the solid phase.
- the Wash I Solution additionally contains an alcohol (e.g., ethanol or methanol).
- the alcohol concentration is at 25-80% (e.g., 30-40%, 40-50%, 35-45%, 55-65%, 60-70%, 65-75%, 70-80%, 30%, 40%, 55%, 60%, 70%, or 75%).
- Wash I Solution contains ethanol at a concentration of 70%.
- Wash I Solution contains methanol at a concentration of 80%.
- the Wash II Solution contains a buffer, alcohol, and an optional chelator (e.g., EDTA or CDTA).
- the Wash II Solution provides for a final wash to remove any residual biological material.
- the buffer composition may be Tris-HCl, such as at pH 6-8 (e.g., pH 6.5, 7 or 7.5).
- the buffer concentration may be at 50-150 mM (e.g., 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 120 mM, or 140 mM).
- the Wash II Solution may additionally contain an alcohol (e.g., ethanol or methanol).
- the alcohol concentration may be at 50-90% (e.g., 55-65%, 60-70%, 65-75%, 70-80%, 55%, 60%, 60%, 75%, 80%, or 85%).
- the EDTA concentration may be at 1-20 mM (e.g., at 5-10 mM, 7-15 mM, 10-17 mM, 15-20 mM, 2 mM, 4 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 15 mM, 17 mM, or 19 mM).
- Wash II contains ethanol at a concentration of 80%, and EDTA at a concentration of 8 mM.
- Wash II contains ethanol at a concentration of 70%, and EDTA at a concentration of 10 mM. In certain embodiments, Wash II contains methanol at a concentration of 60%, and EDTA at a concentration of 12 mM. In other embodiments, Wash II contains methanol at a concentration of 75%, and EDTA at a concentration of 9 mM.
- the DNase Wash Solution contains an alcohol (e.g., ethanol or methanol), salt, and a chelating agent (e.g., EDTA or CDTA).
- the alcohol concentration may be at 10-50% (e.g., at 10-30%, 20-40%, 30-50%, 15%, 20%, 25%, 30%, 35%, or 45%).
- the alcohol may be ethanol at a concentration of 50%.
- the DNase Wash Solution may contain a salt, such as a lithium salt (e.g., lithium chloride, lithium bromide).
- the lithium salt concentration may be at 2-5 M, (e.g., 3-4 M, 2 M, 3 M, 4 M, or 5 M).
- the DNase Wash Solution may contain lithium chloride at a concentration of 4 M.
- the formulation may further contain a chelating agent.
- the chelating agent may be EDTA.
- the chelating agent may be citrate.
- the chelating agent may be at a concentration of 25-100 mM (e.g., 30-70 mM, 40-80 mM, 50-90 mM, 35 mM, 45 mM, 50 mM, 60 mM, 75 mM, 85 mM, or 95 mM trisodium citrate).
- a DNase Wash Solution contains ethanol at a concentration of 30%, LiCl at a concentration of 4M, and EDTA at a concentration of 50 mM. In other embodiments, a DNase Wash Solution contains ethanol at a concentration of 40%, LiCl at a concentration of 5M, and EDTA at a concentration of 65 mM.
- Elution Solutions Substantially undegraded nucleic acids (e.g., DNA or RNA) that are bound to the solid support as a result of the isolation procedure can be eluted using an Elution Solution.
- the simplicity of the reagents used in lysing the biological material and binding of the nucleic acid to the solid support, and in washing the solid support taught by the present invention lends itself to a simple Elution Solution.
- Elution Solutions are known to those having ordinary skilled in the art.
- VersageneTM DNA Elution Solution may be used for eluting bound substantially undegraded DNA.
- Tris-EDTA (TE) may be used for eluting bound substantially undegraded DNA.
- Substantially undegraded RNA which is bound to the solid support, may be eluted using an RNA Elution Solution.
- VersageneTM RNA Elution Solution (Gentra Systems, Inc., Minneapolis, Minn.) may be used for eluting bound substantially undegraded RNA.
- RNase-free water may be used to elute bound substantially undegraded RNA.
- water may be treated with a substance that inactivates RNases, such as diethyl pyrocarbonate (DEPC), and used for eluting RNA.
- DEPC diethyl pyrocarbonate
- Other RNA Elution Solutions known to those having ordinary skill in the art also may be used.
- Gentra Solid Phase RNA Elution Solution (Gentra Systems, Inc., Minneapolis, Minn.) may be used.
- solid supports include, for example, silica-based supports such as glass fiber, or other materials such as cellulose, cellulose acetate, nitrocellulose, nylon, polyester, polyethersulfone, polyolefin, polyvinylidene fluoride, and combinations thereof.
- the solid support may be encased or immobilized in a vessel to enable plug-flow or continuous-flow DNA isolation methods.
- the material of the solid support may be packed so as to create a freestanding solid support such as a membrane, disk, or cylinder that may be immobilized or encased in a suitable vessel, such as a tube or plate.
- the solid support may be fibrous or particulate to allow optimal contact with a biological material.
- the size of the solid support suitable for use with the reagents of this invention may vary according to the volume of the material (e.g., a biological material). For example, glass fiber membranes may be cut to different sizes, in order to allow for the binding, purification and elution of different quantities of DNA.
- the shape of the solid support suitable for use with the reagents of this invention may be, for example, a sheet, a precut disk, cylinder, single fiber, or a solid support composed of particulates.
- the material of the solid support may be packed so as to create a freestanding solid support such as a membrane, disk, or cylinder that may be immobilized or encased in a suitable vessel.
- the solid support is contained in an appropriate vessel, e.g., a paper form (such as a Guthrie card), a microcentrifuge tube, a spin tube, a 96-well plate, a chamber, or a cartridge.
- An example is Whatman D glass fiber membrane within a basket and placed inside a 2 mL microfuge tube. If a solid support has fibers, it may be encased in a suitable vessel so as to pack the fibers appropriately, allow for optimal nucleic acid binding, and the washing away of contaminants such as protein, phospholipids, etc.
- the solid support may be pre-treated with an RNase solution in order to degrade RNA present in the sample (e.g., a biological sample).
- RNase-treated columns such as the ones offered by Gentra Systems, Inc., Minneapolis, Minn.
- the RNase-treated columns degrade RNA that is present in a sample (e.g., a biological sample). Additionally, using the pre-treated columns eliminates the need for a separate RNase digestion step, as is required in some DNA isolation methods.
- a DNA Lysis Solution may be added directly to the material used in making the solid support (e.g., fibers, etc.), and may be allowed to dry before it is made into the final user-ready form (e.g., paper, swab, disk, plug, column, etc.).
- the present invention also provides methods for purifying DNA, or RNA, or both, from material (e.g., biological material) that has been preserved in stabilization reagents (“Stabilized Sample”), including reagents employed under the trade names of PaxgeneTM, RNAsafer®, RNAlater®, and TempusTM solutions.
- Stabilized Sample including reagents employed under the trade names of PaxgeneTM, RNAsafer®, RNAlater®, and TempusTM solutions.
- the reagents and solid supports taught in the invention lend themselves to alternate isolation methods.
- a diluent is added to the biological material in the presence of the stabilization reagent to facilitate preparation of a crude lysate prior to further purification of the Stabilized Sample.
- a Stabilized Sample is contacted with a Solubilization Solution before it is contacted with a Lysis Solution.
- a Solubilization Solution may not be required.
- the Lysis Solution and the Solubilization Solution may be combined.
- a Lysis Solution is contacted with a Stabilized Sample before the sample is contacted with a solid support.
- the Lysis Solution is used to lyse the material (e.g., biological material) and release nucleic acids into a lysate, before adding the lysate to the solid support. Additionally, the Lysis Solution prevents the deleterious effects of harmful enzymes such as nucleases.
- the Lysis Solution volume may be scaled up or down depending on the volume of the Stabilized Sample. Once the Stabilized Sample is lysed, the lysate is then added to the solid support. In other instances, the Lysis Solution may be added directly to the solid support, thereby eliminating a step, and further simplifying the method. In this embodiment, the Lysis Solution may be applied to the solid support and then dried on the solid support before contacting the Stabilized Sample with the pre-treated solid support.
- Enzymes such as RNase and DNase may be added either directly to the solid support to pre-treat the column, or added to the Lysis Solution to degrade contaminating RNA or DNA present in the sample.
- Using the pre-treated columns with Lysis and/or RNase or DNase eliminates the need for a separate lysis and/or nuclease digestion steps, as is typically required in conventional methods.
- the binding of the nucleic acid to the solid support can be improved by employing a Binding Solution.
- the binding may be improved through significant increase in salt concentration, by dehydration, or by both.
- any remaining biological material is optionally removed by suitable means such as centrifugation, pipetting, pressure, vacuum, or by a combined use of these means with a Wash Solution, such that the nucleic acids are left bound to the solid support.
- suitable means such as centrifugation, pipetting, pressure, vacuum, or by a combined use of these means with a Wash Solution, such that the nucleic acids are left bound to the solid support.
- the wash steps may be repeated depending on the tenaciousness of the sample type and amount of non-nucleic acid biological material in the sample.
- the remainder of the non-nucleic acid biological material which includes proteins, phospholipids, etc., may be removed first by centrifugation. By doing this, the unbound contaminants are separated from the solid support.
- the wash steps rid the solid support of substantially all contaminants, and leave behind nucleic acid preferentially bound to the solid support.
- bound nucleic acids may be eluted using an adequate amount of an Elution Solution known to those having ordinary skill in the art.
- the solid support may then be centrifuged, or subjected to pressure or vacuum, in order to release the nucleic acid from the solid support, and can then be collected in a suitable vessel.
- FIG. 1 is a flow diagram depicting a procedure to isolate DNA, RNA, or both, from a sample using the present invention.
- users may perform isolation of only DNA from a sample according to the methods featured in the invention.
- users may perform isolation of only RNA according to the methods featured in the invention.
- users choosing to perform isolation of both RNA and DNA from the same sample would divide the sample following its collection.
- users choosing to perform isolation of both RNA and DNA from the same sample would divide the sample following a solubilization step.
- the reagents, methods and kits featured in the present invention provide substantially pure and undegraded nucleic acids with relatively little contaminating impurities such that the nucleic acids may be used in downstream processes known to those having ordinary skill in the art.
- the invention features, inter alia, a kit that includes specific protocols, which in combination with the reagents and optionally the solid supports described herein, may be used for purifying DNA, RNA, or both DNA and RNA from samples according to the methods of the invention.
- Substantially pure, undegraded nucleic acids are nucleic acids that is suitable for use in subsequent analyses, including, but not limited to, nucleic acid quantification, restriction enzyme digestion, DNA sequencing, hybridization technologies, such as Southern Blotting, etc., amplification methods such as Polymerase Chain Reaction (PCR), Ligase Chain Reaction (LCR), Nucleic Acid Sequence Based Amplification (NASBA), Self-sustained Sequence Replication (SSR or 3SR), Strand Displacement Amplification (SDA), and Transcription Mediated Amplification (TMA), Quantitative PCR (qPCR), or other DNA analyses, as well as RT-PCR, in vitro translation, Northern blotting, microarray analysis and other RNA analyses.
- PCR Polymerase Chain Reaction
- LCR Ligase Chain Reaction
- NASBA Nucleic Acid Sequence Based Amplification
- SSR or 3SR Self-sustained Sequence Replication
- SDA Strand Displacement Amplification
- TMA Transcription Mediated Amplification
- PaxgeneTM Collection Tubes PreAnalytiXTM, Valencia, Calif.
- the resulting sample pellets were not readily soluble in the Lysis Solution (6 M LiCl, 5% Triton X-100, 5% DGME, 10 mM EDTA, 100 mM TRIZMA, pH 8.8), and therefore a Solubilization Solution was used.
- One-hundred and fifty ⁇ l of Solubilization Solution 38 mM TRIZMA base, 12 mM TRIZMA HCl, 10 mM EDTA, 5% Triton X-100 were added to the sample. Resuspending the pellet in water or Tris helped solubilize the pellet in the Lysis Solution in most, but not all embodiments. For example, blood donors with high or abnormal protein levels would fail this RNA isolation due to increased protein contamination.
- RNA binding to the solid support of the present invention in Lysis Solution optimally takes place at pH 8.5-9.5. In this example, the low pH of the pellet lowers the overall pH of the Solubilization Solution, in some embodiments out of this optimal range and also favors protein binding.
- adding a volume of buffer at the correct binding pH absorbs any trace acidic carryover from the pellet and allowed the isolation process to proceed without failure. It is recognized that the pH of the buffer of the Solubilization Solution, therefore, may require adjustment depending on the pH of the pellet carried over for the Stabilized Sample.
- Lysis Solution Three-hundred ⁇ l of Lysis Solution were added to the sample and mixed with each sample. In this instance, the pellet did not require lysis, but the Lysis Solution formulation (6 M LiCl, 5% Triton X-100, 5% DGME, 10 mM EDTA, 100 mM TRIZMA, pH 8.8) facilitated binding the target molecules to the solid support.
- Ten ⁇ L of a Proteinase K Solution were added to each sample and each sample was incubated for 15 minutes at on ice. The entire sample was added to the Binding Column (Whatman D glass fiber membrane within a basket and placed inside a 2 mL microfuge tube) and centrifuged >13,000 ⁇ g for 1 minute.
- RNA obtained by the method described above purified and resuspended RNA was loaded onto a 1% agarose gel and subjected to separation. RNA obtained by the above method was intact and essentially free of DNA.
- PaxgeneTM Collection Tubes PreAnalytiXTM, Valencia, Calif.
- Binding Solution 10 M LiCl, 10% DGME, 100 mM Tris
- Wash I Solution 5 M LiCl, 55% ethanol
- Both solutions allowed genomic DNA to bind to the glass fiber solid support.
- the bound DNA was washed once with 400 ⁇ L of Wash I Solution (5 M LiCl, 55% ethanol), and twice with 200 ⁇ L with Wash II Solution (70% ethanol, 5 mM EDTA, 100 mM Tris, pH 7).
- the DNA was subsequently eluted in TE buffer (Tris-EDTA).
- the resulting pellet was not easily visible, but is soluble directly within the Lysis Solution and can be added directly to the glass fiber solid support without any other binding reagents.
- the pellet was solubilized by the addition of 300 ⁇ L of Lysis Solution (6 M LiCl, 5% Triton X-100, 5% DGME, 10 mM EDTA, 100 mM TRIZMA, pH 8.8, plus 3 ⁇ L TCEP) and vortexed 60 seconds.
- the samples were added to the Binding Column and centrifuged at 3000 ⁇ g for 60 seconds.
- the samples were transferred to a new tube.
- the RNA was washed by adding 400 ⁇ L Wash I, spinning at 3000 ⁇ g for 30 seconds.
- the technology of the TempusTM collection tube alleviates the need for any DNAse treatment. Therefore, the samples were washed by adding 200 ⁇ L Wash II and spinning at 3000 ⁇ g for 30 seconds. 200 ⁇ L Wash II was added and the samples spun at 3000 ⁇ g for 120 seconds. 50 ⁇ L of RNase-free water was added to elute the RNA and the samples were spun at 3000 ⁇ g for one minute.
- RNA yields equal or better to an equivalent volume of blood collected in EDTA tubes or Paxgene collection tubes and isolated with the procedure in Examples 1 and 2 or using PaxgeneTM RNA Purification protocol for blood.
- TempusTM tubes Three mL of blood was drawn from donors into TempusTM tubes, which contain about 6 ml of the TempusTM stabilizing agent, and mixed at ⁇ 25° C. Samples were incubated at room temperature for about two hours. The sample was then decanted into a 50 ml tube, and 3 ml of 95% ethanol was added, to yield a total volume of about 12 ml. The tube was votexed for about 120 seconds, and then centrifuged at 6000 ⁇ g for 30-60 minutes. The supernatant was decanted, and the tube inverted for about 120 seconds to dry the cell pellet.
- the pellet was solubilized by the addition of 300 ⁇ L of Lysis Solution (6 M LiCl, 5% Triton X-100, 5% DGME, 10 mM EDTA, 100 mM TRIZMA, pH 8.8, plus 3 ⁇ L TCEP) and vortexed 60 seconds.
- the samples were added to the Binding Column and centrifuged at 3000 ⁇ g for 60 seconds. The samples were transferred to a new tube.
- the RNA was washed by adding 400 ⁇ L Wash I, spinning at 3000 ⁇ g for 120 seconds. Fifty ⁇ L of DNAse (25 U/50 ⁇ L) was added, and allowed to incubate at room temperature for about 15 minutes.
- DNAse wash (3.5 M Lithium Chloride, 50 mM Sodium Citrate and 30% Ethanol) was added, and the tube is centrifuged at 3000 ⁇ g for 60 seconds. The supernatant was decanted and 200 ⁇ L Wash II solution is added, followed by spinning at 3000 ⁇ g for 60 seconds. 200 ⁇ L Wash II was added and the samples spun at 3000 ⁇ g for 120 seconds. 50 ⁇ L of Elution Solution (Nuclease free water, or Diethylpyrocarbonate treated water or 10 mM Tris, 0.1 mM EDTA, pH 7.5) was added to elute the RNA and the samples were spun at 3000 ⁇ g for one minute.
- Elution Solution Nuclease free water, or Diethylpyrocarbonate treated water or 10 mM Tris, 0.1 mM EDTA, pH 7.5
- FIG. 2 shows that adding ethanol in lieu of PBS (as in Example 3) in the initial dilution step allows a much greater yield of RNA to be recovered at a lower centrifugation speed. Maximal yields in PBS required a centrifugation speed of 5500 ⁇ g while similar yields can now be obtained at 3000 ⁇ g in ethanol. 3000 ⁇ g is a much more common centrifuge speed commonly found in laboratories.
- the inventors also tested different concentrations of alcohol as a Diluent in this method. The results are shown in FIG. 3 .
- the graph shows yields obtained when using different concentrations of alcohols as a diluent. All tubes had the following:
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/265,996 US20060105372A1 (en) | 2004-11-05 | 2005-11-03 | Compositions and methods for purifying nucleic acids from stabilization reagents |
US16/201,204 US10947527B2 (en) | 2004-11-05 | 2018-11-27 | Compositions and methods for purifying nucleic acids from stabilization reagents |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62551304P | 2004-11-05 | 2004-11-05 | |
US71645105P | 2005-09-13 | 2005-09-13 | |
US11/265,996 US20060105372A1 (en) | 2004-11-05 | 2005-11-03 | Compositions and methods for purifying nucleic acids from stabilization reagents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/201,204 Continuation US10947527B2 (en) | 2004-11-05 | 2018-11-27 | Compositions and methods for purifying nucleic acids from stabilization reagents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060105372A1 true US20060105372A1 (en) | 2006-05-18 |
Family
ID=35843671
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/265,996 Abandoned US20060105372A1 (en) | 2004-11-05 | 2005-11-03 | Compositions and methods for purifying nucleic acids from stabilization reagents |
US16/201,204 Active 2026-04-15 US10947527B2 (en) | 2004-11-05 | 2018-11-27 | Compositions and methods for purifying nucleic acids from stabilization reagents |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/201,204 Active 2026-04-15 US10947527B2 (en) | 2004-11-05 | 2018-11-27 | Compositions and methods for purifying nucleic acids from stabilization reagents |
Country Status (9)
Country | Link |
---|---|
US (2) | US20060105372A1 (ko) |
EP (1) | EP1809744B1 (ko) |
JP (1) | JP5390772B2 (ko) |
KR (2) | KR20070097430A (ko) |
CN (1) | CN101124321B (ko) |
AU (1) | AU2005305012C1 (ko) |
CA (1) | CA2586532C (ko) |
NO (1) | NO20072722L (ko) |
WO (1) | WO2006052680A1 (ko) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030073830A1 (en) * | 2001-10-12 | 2003-04-17 | Heath Ellen M. | Compositions and methods for using a solid support to purify RNA |
US20050032105A1 (en) * | 2001-10-12 | 2005-02-10 | Bair Robert Jackson | Compositions and methods for using a solid support to purify DNA |
US20050191760A1 (en) * | 1997-09-17 | 2005-09-01 | Heath Ellen M. | Apparatuses and methods for isolating nucleic acid |
US20060252142A1 (en) * | 2005-05-06 | 2006-11-09 | Hitachi High-Technologies Corporation | Method for nucleic acid isolation and an instrument for nucleic acid isolation |
US20070043216A1 (en) * | 2001-10-12 | 2007-02-22 | Gentra Systems, Inc. | Compositions and methods for using a solid support to purify RNA |
US20070092403A1 (en) * | 2005-10-21 | 2007-04-26 | Alan Wirbisky | Compact apparatus, compositions and methods for purifying nucleic acids |
US20070202511A1 (en) * | 2006-02-28 | 2007-08-30 | Sigma-Aldrich Co. | Methods and compositions for the rapid isolation of small RNA molecules |
US20090053704A1 (en) * | 2007-08-24 | 2009-02-26 | Natalia Novoradovskaya | Stabilization of nucleic acids on solid supports |
US20090155838A1 (en) * | 2007-11-28 | 2009-06-18 | Smart Tube, Inc. | Devices, systems and methods for the collection, stimulation, stabilization, and analysis of a biological sample |
US20090191596A1 (en) * | 2005-02-18 | 2009-07-30 | Gen-Probe Incorporated | Alkaline shock-based preparation of nucleic acids |
DE102008044721A1 (de) * | 2008-08-28 | 2010-03-04 | Forschungszentrum Jülich GmbH | Verfahren zur Isolierung von Nukleinsäuren aus nukleinsäurehaltigen Proben sowie ein dazu geeignetes Testkit |
US20100129801A1 (en) * | 2007-07-26 | 2010-05-27 | Gerald Krueger | Non-invasive recovery of rna and analysis of gene expression in skin |
US20100167271A1 (en) * | 2008-12-30 | 2010-07-01 | Streck, Inc. | Method for screening blood using a preservative that may be in a substantially solid state form |
US20100184069A1 (en) * | 2009-01-21 | 2010-07-22 | Streck, Inc. | Preservation of fetal nucleic acids in maternal plasma |
US20100209930A1 (en) * | 2009-02-18 | 2010-08-19 | Streck, Inc. | Preservation of cell-free nucleic acids |
US20110059455A1 (en) * | 2009-09-03 | 2011-03-10 | Becton, Dickinson And Company | Methods and compositions for direct chemical lysis |
US20110111410A1 (en) * | 2009-11-09 | 2011-05-12 | Streck, Inc. | Stabilization of rna in intact cells within a blood sample |
US20140087366A1 (en) * | 2012-09-19 | 2014-03-27 | Beckman Coulter, Inc. | USE OF DIVALENT IONS, PROTEASES, DETERGENTS, AND LOW pH IN THE EXTRACTION OF NUCLEIC ACIDS |
EP2913399A4 (en) * | 2012-10-26 | 2016-07-13 | Kaneka Corp | METHOD OF PREPARING RNA |
WO2017044710A1 (en) * | 2015-09-11 | 2017-03-16 | Corning Incorporated | Compositions and methods for nucleic acid purification from blood samples |
WO2017127399A1 (en) * | 2016-01-19 | 2017-07-27 | El-Fahmawi Bassam | Method and device for maintaining mammalian and microbial cells viable and intact during ambient temperature transport and storage |
WO2017189746A1 (en) * | 2016-04-27 | 2017-11-02 | Gen-Probe Incorporated | Blood cell lysis reagent |
US9956281B2 (en) | 2011-05-04 | 2018-05-01 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
US10091984B2 (en) | 2013-07-24 | 2018-10-09 | Streck, Inc. | Compositions and methods for stabilizing circulating tumor cells |
CN109312330A (zh) * | 2016-02-11 | 2019-02-05 | 萨斯特德特股份有限两合公司 | 用于从全血中分离核酸的装置和方法 |
US10966421B2 (en) | 2002-10-16 | 2021-04-06 | Streck, Inc. | Method and device for collecting and preserving cells for analysis |
US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
US20220090165A1 (en) * | 2018-10-23 | 2022-03-24 | Toray Industries, Inc. | Method of collecting nucleic acid and kit for collection of nucleic acid |
US11299764B2 (en) | 2015-11-20 | 2022-04-12 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
US11313855B2 (en) | 2018-09-25 | 2022-04-26 | Siemens Healthcare Diagnostics Inc. | Methods and compositions for removing biotin interference from assays using conjugated molecular traps |
US11506655B2 (en) | 2016-07-29 | 2022-11-22 | Streck, Inc. | Suspension composition for hematology analysis control |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005057334A1 (de) | 2005-11-28 | 2007-06-06 | Aj Innuscreen Gmbh | Verfahren zur Isolierung von Nukleinsäuren aus beliebigen Ausgangsmaterialien |
EP2163620A1 (de) * | 2008-09-03 | 2010-03-17 | Qiagen GmbH | Verfahren zum Isolieren und Reinigen von Nukleinsäuren |
CN101816299B (zh) * | 2010-04-29 | 2012-11-21 | 杭州锐创生物技术有限公司 | 一种离体组织稳定保护剂及其制备方法 |
CN102559659B (zh) * | 2011-12-28 | 2013-07-31 | 浙江工业大学 | 一种用乙醇分级沉淀纯化dna的方法 |
SG10201807736SA (en) * | 2014-03-07 | 2018-10-30 | Dna Genotek Inc | Composition and method for stabilizing nucleic acids in biological samples |
CN105255855A (zh) * | 2014-07-10 | 2016-01-20 | 上海艾迪康医学检验所有限公司 | 在固体表面保存核酸的方法及其保存液 |
WO2016144137A1 (ko) * | 2015-03-12 | 2016-09-15 | 재단법인 아산사회복지재단 | 순환 유리 핵산의 분리 방법 |
GB201609115D0 (en) * | 2016-05-24 | 2016-07-06 | Moorlodge Biotech Ventures Ltd | Isolating nucleic acids |
JP2020510420A (ja) * | 2017-02-27 | 2020-04-09 | ミダイアグノスティクス・エヌブイmiDiagnostics NV | 核酸を精製し増幅するためのシステムおよび方法 |
US20220090048A1 (en) * | 2019-01-25 | 2022-03-24 | Sekisui Chemical Co., Ltd. | Method for isolating nucleic acid, nucleic acid isolation kit, and inspection chip |
CN111172240A (zh) * | 2020-03-06 | 2020-05-19 | 苏州博方生物技术有限公司 | 一种核酸释放剂及hpv病毒核酸检测试剂盒 |
CN114517196A (zh) * | 2022-02-25 | 2022-05-20 | 杭州诺辉健康科技有限公司 | 一种血浆游离miRNA提取方法及其应用 |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4870006A (en) * | 1986-07-24 | 1989-09-26 | Codon | Antigenic material for a chagas' disease detection system |
US4996297A (en) * | 1987-10-07 | 1991-02-26 | Zonagen, Inc. | Recombinantly expressed rabbit zona pellucida polypeptides |
US5132207A (en) * | 1984-07-05 | 1992-07-21 | Gen-Probe Incorporated | Accelerated nucleic acid reassociation method |
US5155018A (en) * | 1991-07-10 | 1992-10-13 | Hahnemann University | Process and kit for isolating and purifying RNA from biological sources |
US5268526A (en) * | 1988-07-29 | 1993-12-07 | E. I. Du Pont De Nemours And Company | Overexpression of phytochrome in transgenic plants |
US5596092A (en) * | 1990-02-14 | 1997-01-21 | Talent S.R.L. | Extraction of genomic DNA from blood using cationic detergents |
US5637687A (en) * | 1993-08-31 | 1997-06-10 | Wiggins; James C. | Methods and compositions for isolating nucleic acids |
US5773700A (en) * | 1992-03-19 | 1998-06-30 | Andoz Ltd | Constructs containing impatiens necrotic spot tospovirus RNA and methods of use thereof |
US5939259A (en) * | 1997-04-09 | 1999-08-17 | Schleicher & Schuell, Inc. | Methods and devices for collecting and storing clinical samples for genetic analysis |
US5958677A (en) * | 1997-07-28 | 1999-09-28 | The New York Blood Center, Inc. | Method for purifying viral nucleic acids |
US5985572A (en) * | 1993-02-01 | 1999-11-16 | Qiagen N.V. | Quaternary amine surfactant and methods of using same in isolation of RNA |
US6037465A (en) * | 1994-06-14 | 2000-03-14 | Invitek Gmbh | Universal process for isolating and purifying nucleic acids from extremely small amounts of highly contaminated various starting materials |
US6384298B1 (en) * | 1988-12-05 | 2002-05-07 | Genpharm International | Transgenic mice depleted in a mature lymphocytic cell-type |
US20020106686A1 (en) * | 2001-01-09 | 2002-08-08 | Mckernan Kevin J. | Methods and reagents for the isolation of nucleic acids |
US20030073830A1 (en) * | 2001-10-12 | 2003-04-17 | Heath Ellen M. | Compositions and methods for using a solid support to purify RNA |
US20030092045A1 (en) * | 2001-11-06 | 2003-05-15 | Cortex Biochem, Inc. | Isolation and purification of nucleic acids |
US20030106107A1 (en) * | 1998-08-12 | 2003-06-05 | Kazuko Shinozaki | Genes encoding plant transcription factors |
US20030157492A1 (en) * | 2002-02-15 | 2003-08-21 | Heath Ellen M. | Method to isolate DNA |
US6617170B2 (en) * | 2000-11-08 | 2003-09-09 | Becton, Dickinson And Company | Method and device for collecting and stabilizing a biological sample |
US20040019196A1 (en) * | 2001-10-12 | 2004-01-29 | Robert Jackson Bair | Compositions and methods for using a solid support to purify RNA |
US20040245163A1 (en) * | 2003-06-06 | 2004-12-09 | Gary Lim | Purification device for ribonucleic acid in large volumes, and method |
US20050059054A1 (en) * | 2003-07-25 | 2005-03-17 | Richard Conrad | Methods and compositions for preparing RNA from a fixed sample |
US20050153292A1 (en) * | 2002-01-18 | 2005-07-14 | Patrick Stordeur | Method to determine in vivo nucleic acid levels |
US20060099210A1 (en) * | 2002-06-25 | 2006-05-11 | Serono Genetics Institute S. A. | Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders |
US7115719B2 (en) * | 2003-12-16 | 2006-10-03 | Gentra Systems, Inc. | Formulations and methods for denaturing proteins |
US20070087369A1 (en) * | 2005-07-13 | 2007-04-19 | Sigma Aldrich Co. | Method for the Isolation of RNA from Biological Sources |
US20070092403A1 (en) * | 2005-10-21 | 2007-04-26 | Alan Wirbisky | Compact apparatus, compositions and methods for purifying nucleic acids |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS594664B2 (ja) | 1976-11-10 | 1984-01-31 | 株式会社日立製作所 | イオン交換クロマトグラフイ− |
US4483920A (en) | 1982-05-17 | 1984-11-20 | Hahnemann University | Immobilization of message RNA directly from cells onto filter material |
DE3639949A1 (de) | 1986-11-22 | 1988-06-09 | Diagen Inst Molekularbio | Verfahren zur trennung von langkettigen nukleinsaeuren |
US5599667A (en) | 1987-03-02 | 1997-02-04 | Gen-Probe Incorporated | Polycationic supports and nucleic acid purification separation and hybridization |
US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
US5496562A (en) | 1988-10-05 | 1996-03-05 | Flinders Technologies Pty Ltd | Solid medium and method for DNA storage |
US5234809A (en) | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
US5010183A (en) | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
US5580970A (en) | 1989-12-01 | 1996-12-03 | Amoco Corporation | Detection of HPV transcripts |
US5652141A (en) | 1990-10-26 | 1997-07-29 | Oiagen Gmbh | Device and process for isolating nucleic acids from cell suspension |
DE4034036C2 (de) | 1990-10-26 | 1994-03-03 | Diagen Inst Molekularbio | Vorrichtung und Verfahren zur Isolierung von Nukleinsäuren aus Zellsuspensionen |
GB9108604D0 (en) | 1991-04-22 | 1991-06-05 | Nadreph Ltd | Gel products and a process for making them |
CA2067711C (en) | 1991-05-03 | 2000-08-08 | Daniel Lee Woodard | Solid phase extraction purification of dna |
US5422241A (en) | 1991-07-03 | 1995-06-06 | Ambion, Inc. | Methods for the recovery of nucleic acids from reaction mixtures |
US5346994A (en) | 1992-01-28 | 1994-09-13 | Piotr Chomczynski | Shelf-stable product and process for isolating RNA, DNA and proteins |
DE4321904B4 (de) | 1993-07-01 | 2013-05-16 | Qiagen Gmbh | Verfahren zur chromatographischen Reinigung und Trennung von Nucleinsäuregemischen |
GB9314249D0 (en) | 1993-07-09 | 1993-08-18 | Proofname Ltd | Purification method and apparatus |
ATE302208T1 (de) | 1994-02-11 | 2005-09-15 | Qiagen Gmbh | Verfahren zur trennung von doppelstrang/einzelstrangnukleinsäurestrukturen |
EP0673638A3 (en) | 1994-03-24 | 1996-10-16 | Kao Corp | Cosmetic composition containing antibodies. |
WO1995034569A1 (de) | 1994-06-14 | 1995-12-21 | Invitek Gmbh | Universelles verfahren zur isolierung und reinigung von nukleinsäuren aus extrem geringen mengen sowie sehr stark verunreinigten unterschiedlichsten ausgangsmaterialien |
JP3163224B2 (ja) | 1994-10-14 | 2001-05-08 | 三菱レイヨン株式会社 | 菌体または固定化菌体の懸濁液の保存方法 |
GB9425138D0 (en) | 1994-12-12 | 1995-02-08 | Dynal As | Isolation of nucleic acid |
US5945515A (en) | 1995-07-31 | 1999-08-31 | Chomczynski; Piotr | Product and process for isolating DNA, RNA and proteins |
US5973137A (en) | 1996-02-13 | 1999-10-26 | Gentra Systems, Inc. | Low pH RNA isolation reagents, method, and kit |
JP3940935B2 (ja) | 1996-06-11 | 2007-07-04 | 東洋紡績株式会社 | プラスミドdnaの抽出精製方法 |
US5939262A (en) | 1996-07-03 | 1999-08-17 | Ambion, Inc. | Ribonuclease resistant RNA preparation and utilization |
US5677124A (en) | 1996-07-03 | 1997-10-14 | Ambion, Inc. | Ribonuclease resistant viral RNA standards |
EP0818461B1 (en) | 1996-07-12 | 2005-09-28 | Toyo Boseki Kabushiki Kaisha | Method for isolating ribonucleic acid |
JP3333691B2 (ja) | 1996-09-25 | 2002-10-15 | 株式会社日本自動車部品総合研究所 | タイヤ空気圧検知装置 |
US6218531B1 (en) | 1997-06-25 | 2001-04-17 | Promega Corporation | Method of isolating RNA |
US6207370B1 (en) | 1997-09-02 | 2001-03-27 | Sequenom, Inc. | Diagnostics based on mass spectrometric detection of translated target polypeptides |
JP2001516731A (ja) | 1997-09-17 | 2001-10-02 | ジエントラ・システムズ・インコーポレーテツド | 核酸を単離するための装置および方法 |
US5972613A (en) * | 1997-12-09 | 1999-10-26 | The Perkin-Elmer Corporation | Methods of nucleic acid isolation |
ZA99493B (en) | 1998-01-30 | 1999-07-22 | Akzo Nobel Nv | Method for the isolation of nucleic acid. |
AU2574299A (en) * | 1998-02-02 | 1999-08-16 | Gentra Systems, Inc. | Eluting reagents, methods and kits for isolating dna |
WO1999039009A1 (en) * | 1998-02-02 | 1999-08-05 | Gentra Systems, Inc. | Processes for isolating, amplifying and characterizing dna |
US6090593A (en) | 1998-05-13 | 2000-07-18 | The United States Of America As Represented By The Secretary Of The Air Force | Isolation of expressed genes in microorganisms |
US6204375B1 (en) | 1998-07-31 | 2001-03-20 | Ambion, Inc. | Methods and reagents for preserving RNA in cell and tissue samples |
US6777210B1 (en) | 1998-09-24 | 2004-08-17 | Ambion, Inc. | Method and reagents for inactivating ribonucleases RNase A, RNase I and RNase T1 |
US6958392B2 (en) | 1998-10-09 | 2005-10-25 | Whatman, Inc. | Methods for the isolation of nucleic acids and for quantitative DNA extraction and detection for leukocyte evaluation in blood products |
DE19856064C2 (de) | 1998-12-04 | 2000-11-30 | Invitek Gmbh | Universelles Verfahren zur Isolierung von DNA aus beliebigen Ausgangsmaterialien |
JP2002534080A (ja) * | 1999-01-06 | 2002-10-15 | インビトロジェン コーポレイション | 核酸分子の単離のための方法および組成物 |
WO2000075306A2 (en) | 1999-04-30 | 2000-12-14 | Cyclops Genome Sciences Limited | Method for producing double stranded polynucleotides |
US6270970B1 (en) | 1999-05-14 | 2001-08-07 | Promega Corporation | Mixed-bed solid phase and its use in the isolation of nucleic acids |
WO2000077235A1 (en) * | 1999-06-16 | 2000-12-21 | University Of Cincinnati | Agent and process for isolation of extra-chromosomal nucleic acids |
US20060276629A9 (en) | 1999-12-17 | 2006-12-07 | Hildebrand William H | Purification and characterization of soluble human HLA proteins |
US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
GB0013658D0 (en) * | 2000-06-05 | 2000-07-26 | Dynal Asa | Nucleic acid isolation |
US6503716B1 (en) | 2000-11-28 | 2003-01-07 | Pe Corporation (Ny) | Compositions and methods for extracting a nucleic acid |
US6818398B2 (en) | 2000-12-29 | 2004-11-16 | The University Of Chicago | Column device for isolation and labeling of nucleic acids |
WO2002065125A1 (en) | 2001-02-13 | 2002-08-22 | Invitrogen Corporation | Methods and compositions for isolation of biological macromolecules |
US6855499B1 (en) | 2001-02-16 | 2005-02-15 | Cortex Biochem, Inc. | Magnetic isolation and purification of nucleic acids |
WO2003033739A1 (en) * | 2001-10-12 | 2003-04-24 | Gentra Systems, Inc. | Compositions and methods for using a solid support to purify rna |
AU2004233035B2 (en) * | 2001-10-12 | 2009-07-23 | Qiagen North American Holdings, Inc. | Compositions and methods for using a solid support to purify RNA |
US20050032105A1 (en) * | 2001-10-12 | 2005-02-10 | Bair Robert Jackson | Compositions and methods for using a solid support to purify DNA |
DE10231659B4 (de) | 2002-07-12 | 2006-01-19 | Preanalytix Gmbh | Zusammensetzung zum Binden von Nukleinsäure an eine Festphase |
GB0217963D0 (en) | 2002-08-02 | 2002-09-11 | Cyclops Genome Sciences Ltd | Purification of nucleic acids |
GB0225197D0 (en) | 2002-10-30 | 2002-12-11 | Univ Sheffield | Surface |
US7790876B2 (en) | 2002-12-20 | 2010-09-07 | E. I. Du Pont De Nemours And Company | Sequences diagnostic for foot and mouth disease |
GB0230102D0 (en) | 2002-12-23 | 2003-01-29 | Spinox Ltd | Apparatus and method for storing proteins |
KR100691372B1 (ko) | 2005-10-19 | 2007-03-12 | 삼성전기주식회사 | 신뢰성이 확보된 전해액을 포함하는 전기 습윤 장치 |
US20070141583A1 (en) | 2005-12-20 | 2007-06-21 | Weiwei Li | Methods of rapid chromatin immunoprecipitation |
US7538190B2 (en) | 2006-02-17 | 2009-05-26 | Polychip Pharmaceuticals Pty Ltd | Methods for the synthesis of two or more dicarba bridges in organic compounds |
US20080026451A1 (en) | 2006-06-15 | 2008-01-31 | Braman Jeffrey C | System for isolating biomolecules from a sample |
US9902189B2 (en) | 2012-12-02 | 2018-02-27 | Smead Manufacturing Company | Vertical pocket folder |
-
2005
- 2005-11-03 KR KR1020077012572A patent/KR20070097430A/ko not_active Application Discontinuation
- 2005-11-03 JP JP2007540037A patent/JP5390772B2/ja active Active
- 2005-11-03 WO PCT/US2005/039837 patent/WO2006052680A1/en active Application Filing
- 2005-11-03 AU AU2005305012A patent/AU2005305012C1/en active Active
- 2005-11-03 EP EP05818780.8A patent/EP1809744B1/en active Active
- 2005-11-03 KR KR1020137031861A patent/KR20130143677A/ko not_active Application Discontinuation
- 2005-11-03 US US11/265,996 patent/US20060105372A1/en not_active Abandoned
- 2005-11-03 CN CN2005800381820A patent/CN101124321B/zh active Active
- 2005-11-03 CA CA2586532A patent/CA2586532C/en active Active
-
2007
- 2007-05-29 NO NO20072722A patent/NO20072722L/no not_active Application Discontinuation
-
2018
- 2018-11-27 US US16/201,204 patent/US10947527B2/en active Active
Patent Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5132207A (en) * | 1984-07-05 | 1992-07-21 | Gen-Probe Incorporated | Accelerated nucleic acid reassociation method |
US4870006A (en) * | 1986-07-24 | 1989-09-26 | Codon | Antigenic material for a chagas' disease detection system |
US4996297A (en) * | 1987-10-07 | 1991-02-26 | Zonagen, Inc. | Recombinantly expressed rabbit zona pellucida polypeptides |
US5268526A (en) * | 1988-07-29 | 1993-12-07 | E. I. Du Pont De Nemours And Company | Overexpression of phytochrome in transgenic plants |
US6384298B1 (en) * | 1988-12-05 | 2002-05-07 | Genpharm International | Transgenic mice depleted in a mature lymphocytic cell-type |
US5596092A (en) * | 1990-02-14 | 1997-01-21 | Talent S.R.L. | Extraction of genomic DNA from blood using cationic detergents |
US5155018A (en) * | 1991-07-10 | 1992-10-13 | Hahnemann University | Process and kit for isolating and purifying RNA from biological sources |
US5773700A (en) * | 1992-03-19 | 1998-06-30 | Andoz Ltd | Constructs containing impatiens necrotic spot tospovirus RNA and methods of use thereof |
US5985572A (en) * | 1993-02-01 | 1999-11-16 | Qiagen N.V. | Quaternary amine surfactant and methods of using same in isolation of RNA |
US5637687A (en) * | 1993-08-31 | 1997-06-10 | Wiggins; James C. | Methods and compositions for isolating nucleic acids |
US6037465A (en) * | 1994-06-14 | 2000-03-14 | Invitek Gmbh | Universal process for isolating and purifying nucleic acids from extremely small amounts of highly contaminated various starting materials |
US5939259A (en) * | 1997-04-09 | 1999-08-17 | Schleicher & Schuell, Inc. | Methods and devices for collecting and storing clinical samples for genetic analysis |
US5958677A (en) * | 1997-07-28 | 1999-09-28 | The New York Blood Center, Inc. | Method for purifying viral nucleic acids |
US20030106107A1 (en) * | 1998-08-12 | 2003-06-05 | Kazuko Shinozaki | Genes encoding plant transcription factors |
US6617170B2 (en) * | 2000-11-08 | 2003-09-09 | Becton, Dickinson And Company | Method and device for collecting and stabilizing a biological sample |
US20020106686A1 (en) * | 2001-01-09 | 2002-08-08 | Mckernan Kevin J. | Methods and reagents for the isolation of nucleic acids |
US20030073830A1 (en) * | 2001-10-12 | 2003-04-17 | Heath Ellen M. | Compositions and methods for using a solid support to purify RNA |
US20040019196A1 (en) * | 2001-10-12 | 2004-01-29 | Robert Jackson Bair | Compositions and methods for using a solid support to purify RNA |
US7148343B2 (en) * | 2001-10-12 | 2006-12-12 | Gentra Systems, Inc. | Compositions and methods for using a solid support to purify RNA |
US20070043216A1 (en) * | 2001-10-12 | 2007-02-22 | Gentra Systems, Inc. | Compositions and methods for using a solid support to purify RNA |
US20030092045A1 (en) * | 2001-11-06 | 2003-05-15 | Cortex Biochem, Inc. | Isolation and purification of nucleic acids |
US20050153292A1 (en) * | 2002-01-18 | 2005-07-14 | Patrick Stordeur | Method to determine in vivo nucleic acid levels |
US20030157492A1 (en) * | 2002-02-15 | 2003-08-21 | Heath Ellen M. | Method to isolate DNA |
US20060099210A1 (en) * | 2002-06-25 | 2006-05-11 | Serono Genetics Institute S. A. | Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders |
US20040245163A1 (en) * | 2003-06-06 | 2004-12-09 | Gary Lim | Purification device for ribonucleic acid in large volumes, and method |
US20050059054A1 (en) * | 2003-07-25 | 2005-03-17 | Richard Conrad | Methods and compositions for preparing RNA from a fixed sample |
US7115719B2 (en) * | 2003-12-16 | 2006-10-03 | Gentra Systems, Inc. | Formulations and methods for denaturing proteins |
US20070087369A1 (en) * | 2005-07-13 | 2007-04-19 | Sigma Aldrich Co. | Method for the Isolation of RNA from Biological Sources |
US20070092403A1 (en) * | 2005-10-21 | 2007-04-26 | Alan Wirbisky | Compact apparatus, compositions and methods for purifying nucleic acids |
Non-Patent Citations (1)
Title |
---|
Lin et al. (Plant Physiol 1992 vol. 99 p. 519) * |
Cited By (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050191760A1 (en) * | 1997-09-17 | 2005-09-01 | Heath Ellen M. | Apparatuses and methods for isolating nucleic acid |
US7776616B2 (en) | 1997-09-17 | 2010-08-17 | Qiagen North American Holdings, Inc. | Apparatuses and methods for isolating nucleic acid |
US8598338B2 (en) | 2001-10-12 | 2013-12-03 | Qiagen North American Holdings, Inc. | Compositions and methods for using a solid support to purify DNA |
US20100160619A1 (en) * | 2001-10-12 | 2010-06-24 | Qiagen North American Holdings, Inc. | Compositions and methods for using a solid support to purify dna |
US20070043216A1 (en) * | 2001-10-12 | 2007-02-22 | Gentra Systems, Inc. | Compositions and methods for using a solid support to purify RNA |
US20050032105A1 (en) * | 2001-10-12 | 2005-02-10 | Bair Robert Jackson | Compositions and methods for using a solid support to purify DNA |
US20030073830A1 (en) * | 2001-10-12 | 2003-04-17 | Heath Ellen M. | Compositions and methods for using a solid support to purify RNA |
US7767804B2 (en) | 2001-10-12 | 2010-08-03 | Qiagen North American Holdings, Inc. | Compositions and methods for using a solid support to purify RNA |
US7893228B2 (en) | 2001-10-12 | 2011-02-22 | Qiagen North American Holdings, Inc. | Compositions and methods for using a solid support to purify RNA |
US11647743B2 (en) | 2002-10-16 | 2023-05-16 | Streck Llc | Method and device for collecting and preserving cells for analysis |
US10966421B2 (en) | 2002-10-16 | 2021-04-06 | Streck, Inc. | Method and device for collecting and preserving cells for analysis |
US20090191596A1 (en) * | 2005-02-18 | 2009-07-30 | Gen-Probe Incorporated | Alkaline shock-based preparation of nucleic acids |
US8071301B2 (en) * | 2005-02-18 | 2011-12-06 | Gen-Probe Incorporated | Method of isolating nucleic acids from a biological sample |
US8420317B2 (en) * | 2005-02-18 | 2013-04-16 | Gen-Probe Incorporated | Alkaline shock-based method of processing a biological sample |
US7803581B2 (en) * | 2005-02-18 | 2010-09-28 | Gen-Probe Incorporated | Alkaline shock-based preparation of nucleic acids |
US20110008847A1 (en) * | 2005-02-18 | 2011-01-13 | Gen-Probe Incorporated | Method of isolating nucleic acids from a biological sample |
US20060252142A1 (en) * | 2005-05-06 | 2006-11-09 | Hitachi High-Technologies Corporation | Method for nucleic acid isolation and an instrument for nucleic acid isolation |
US20070092403A1 (en) * | 2005-10-21 | 2007-04-26 | Alan Wirbisky | Compact apparatus, compositions and methods for purifying nucleic acids |
US20100256351A1 (en) * | 2006-02-28 | 2010-10-07 | Sigma Aldrich Co. | Methods and compositions for the rapid isolation of small rna molecules |
US9062303B2 (en) | 2006-02-28 | 2015-06-23 | Sigma-Aldrich Co. Llc | Methods and compositions for the rapid isolation of small RNA molecules |
US20070202511A1 (en) * | 2006-02-28 | 2007-08-30 | Sigma-Aldrich Co. | Methods and compositions for the rapid isolation of small RNA molecules |
US20100129801A1 (en) * | 2007-07-26 | 2010-05-27 | Gerald Krueger | Non-invasive recovery of rna and analysis of gene expression in skin |
US8389215B2 (en) * | 2007-07-26 | 2013-03-05 | University Of Utah Research Foundation | Non-invasive recovery of RNA and analysis of gene expression in skin |
US20110230653A1 (en) * | 2007-08-24 | 2011-09-22 | Agilent Technologies, Inc. | Stabilization of nucleic acids on solid supports |
WO2009029433A3 (en) * | 2007-08-24 | 2009-04-23 | Agilent Technologies Inc | Stabilization of nucleic acids on solid supports |
US20090053704A1 (en) * | 2007-08-24 | 2009-02-26 | Natalia Novoradovskaya | Stabilization of nucleic acids on solid supports |
US20090155838A1 (en) * | 2007-11-28 | 2009-06-18 | Smart Tube, Inc. | Devices, systems and methods for the collection, stimulation, stabilization, and analysis of a biological sample |
DE102008044721A1 (de) * | 2008-08-28 | 2010-03-04 | Forschungszentrum Jülich GmbH | Verfahren zur Isolierung von Nukleinsäuren aus nukleinsäurehaltigen Proben sowie ein dazu geeignetes Testkit |
DE102008044721B4 (de) * | 2008-08-28 | 2012-07-19 | Forschungszentrum Jülich GmbH | Verfahren zur Isolierung von Nukleinsäuren aus nukleinsäurehaltigen Proben sowie ein dazu geeignetes Testkit |
US20100167271A1 (en) * | 2008-12-30 | 2010-07-01 | Streck, Inc. | Method for screening blood using a preservative that may be in a substantially solid state form |
US11634747B2 (en) | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
US20100184069A1 (en) * | 2009-01-21 | 2010-07-22 | Streck, Inc. | Preservation of fetal nucleic acids in maternal plasma |
US20180216165A1 (en) | 2009-02-18 | 2018-08-02 | Streck, Inc. | Preservation of cell-free nucleic acids |
US20100209930A1 (en) * | 2009-02-18 | 2010-08-19 | Streck, Inc. | Preservation of cell-free nucleic acids |
US11761025B2 (en) | 2009-02-18 | 2023-09-19 | Streck Llc | Preservation of cell-free nucleic acids |
US10689686B2 (en) | 2009-02-18 | 2020-06-23 | Streck, Inc. | Preservation of cell-free nucleic acids |
US9926590B2 (en) | 2009-02-18 | 2018-03-27 | Streck, Inc. | Devices and compositions for preservation of cell-free nucleic acids |
US10294513B2 (en) | 2009-02-18 | 2019-05-21 | Streck, Inc. | Preservation of cell-free nucleic acids |
US9657227B2 (en) | 2009-02-18 | 2017-05-23 | Streck, Inc. | Preservation of cell-free RNA in blood samples |
US10144955B2 (en) | 2009-02-18 | 2018-12-04 | Streck, Inc. | Methods for preservation of cell-free nucleic acids |
US8304187B2 (en) | 2009-02-18 | 2012-11-06 | Streck, Inc. | Preservation of cell-free RNA in blood samples |
US10323267B2 (en) | 2009-09-03 | 2019-06-18 | Becton Dickinson And Company | Methods and compositions for direct chemical lysis |
US11434519B2 (en) | 2009-09-03 | 2022-09-06 | Becton, Dickinson And Company | Methods and compositions for direct chemical lysis |
WO2011028887A3 (en) * | 2009-09-03 | 2011-07-28 | Becton, Dickinson And Company | Methods and compositions for direct chemical lysis |
US10190152B2 (en) | 2009-09-03 | 2019-01-29 | Becton, Dickinson And Company | Methods and compositions for direct chemical lysis |
US20110059455A1 (en) * | 2009-09-03 | 2011-03-10 | Becton, Dickinson And Company | Methods and compositions for direct chemical lysis |
US20110111410A1 (en) * | 2009-11-09 | 2011-05-12 | Streck, Inc. | Stabilization of rna in intact cells within a blood sample |
EP3103883A1 (en) | 2009-11-09 | 2016-12-14 | Streck, Inc. | Stabilization of rna in and extracting from intact cells within a blood sample |
US9956281B2 (en) | 2011-05-04 | 2018-05-01 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
US20140087366A1 (en) * | 2012-09-19 | 2014-03-27 | Beckman Coulter, Inc. | USE OF DIVALENT IONS, PROTEASES, DETERGENTS, AND LOW pH IN THE EXTRACTION OF NUCLEIC ACIDS |
US9695413B2 (en) | 2012-10-26 | 2017-07-04 | Kaneka Corporation | RNA preparation method |
EP2913399A4 (en) * | 2012-10-26 | 2016-07-13 | Kaneka Corp | METHOD OF PREPARING RNA |
US10674721B2 (en) | 2013-07-24 | 2020-06-09 | Streck, Inc. | Compositions and methods for stabilizing circulating tumor cells |
US10091984B2 (en) | 2013-07-24 | 2018-10-09 | Streck, Inc. | Compositions and methods for stabilizing circulating tumor cells |
US11547111B2 (en) | 2013-07-24 | 2023-01-10 | Streck, Inc. | Compositions and methods for stabilizing circulating tumor cells |
US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
WO2017044710A1 (en) * | 2015-09-11 | 2017-03-16 | Corning Incorporated | Compositions and methods for nucleic acid purification from blood samples |
US11299764B2 (en) | 2015-11-20 | 2022-04-12 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
WO2017127399A1 (en) * | 2016-01-19 | 2017-07-27 | El-Fahmawi Bassam | Method and device for maintaining mammalian and microbial cells viable and intact during ambient temperature transport and storage |
US20190127729A1 (en) * | 2016-02-11 | 2019-05-02 | Sarstedt Ag & Co. Kg | Device and method for isolating nucleic acids from whole blood |
CN109312330A (zh) * | 2016-02-11 | 2019-02-05 | 萨斯特德特股份有限两合公司 | 用于从全血中分离核酸的装置和方法 |
US11118174B2 (en) * | 2016-02-11 | 2021-09-14 | Sarstedt Ag & Co. Kg | Device and method for isolating nucleic acids from whole blood |
EP3736332A1 (en) * | 2016-04-27 | 2020-11-11 | Gen-Probe Incorporated | Blood cell lysis reagent |
US11162091B2 (en) | 2016-04-27 | 2021-11-02 | Gen-Probe Incorporated | Blood cell lysis reagent |
US11015185B1 (en) | 2016-04-27 | 2021-05-25 | Gen-Probe Incorporated | Blood cell lysis reagent |
WO2017189746A1 (en) * | 2016-04-27 | 2017-11-02 | Gen-Probe Incorporated | Blood cell lysis reagent |
US11506655B2 (en) | 2016-07-29 | 2022-11-22 | Streck, Inc. | Suspension composition for hematology analysis control |
US11313855B2 (en) | 2018-09-25 | 2022-04-26 | Siemens Healthcare Diagnostics Inc. | Methods and compositions for removing biotin interference from assays using conjugated molecular traps |
US20220090165A1 (en) * | 2018-10-23 | 2022-03-24 | Toray Industries, Inc. | Method of collecting nucleic acid and kit for collection of nucleic acid |
Also Published As
Publication number | Publication date |
---|---|
US20190345480A1 (en) | 2019-11-14 |
KR20130143677A (ko) | 2013-12-31 |
WO2006052680A1 (en) | 2006-05-18 |
CA2586532A1 (en) | 2006-05-18 |
AU2005305012B2 (en) | 2012-01-12 |
US10947527B2 (en) | 2021-03-16 |
AU2005305012C1 (en) | 2012-07-19 |
CA2586532C (en) | 2014-03-25 |
JP5390772B2 (ja) | 2014-01-15 |
EP1809744A1 (en) | 2007-07-25 |
EP1809744B1 (en) | 2018-06-06 |
NO20072722L (no) | 2007-08-03 |
KR20070097430A (ko) | 2007-10-04 |
AU2005305012A1 (en) | 2006-05-18 |
CN101124321A (zh) | 2008-02-13 |
JP2008518618A (ja) | 2008-06-05 |
CN101124321B (zh) | 2012-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10947527B2 (en) | Compositions and methods for purifying nucleic acids from stabilization reagents | |
US7767804B2 (en) | Compositions and methods for using a solid support to purify RNA | |
EP1773996B9 (en) | Compositions and methods for using a solid support to purify dna | |
CA2549985C (en) | Formulations and methods for denaturing proteins | |
AU2004233035B2 (en) | Compositions and methods for using a solid support to purify RNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GENTRA SYSTEMS, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAIR, ROBERT JACKSON;PAULSEN, KIM;REEL/FRAME:017202/0097 Effective date: 20060111 |
|
AS | Assignment |
Owner name: QIAGEN NORTH AMERICAN HOLDINGS, INC, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GENTRA SYSTEMS INC.;REEL/FRAME:019241/0713 Effective date: 20060524 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |